The dual peroxisome proliferator–activated receptor α/γ agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin-Reference-Cited by-同舟云学术

The dual peroxisome proliferator–activated receptor α/γ agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin

Published:2007-09 Issue:9 Volume:56 Page:1285-1292
ISSN:0026-0495
Container-title:Metabolism
language:en
Short-container-title:Metabolism

Author:

Tonstad Serena,Retterstøl Kjetil,Ose Leiv,Öhman K. Peter,Lindberg Magnus B.,Svensson Maria

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Reference28 articles.

1. Diabetic dyslipidaemia;Betteridge;Diabetes Obes Metab,2000

2. Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus;Sniderman;Ann Intern Med,2001

3. Diabetic dyslipidemia;Taskinen;Atheroscler Suppl,2002

4. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome;Nesto;Am J Cardiovasc Drugs,2005

5. Low-density lipoprotein subclass patterns and risk of myocardial infarction;Austin;JAMA,1988

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diversity of Solid Forms Promoted by Ball Milling: Characterization and Intrinsic Dissolution Studies of Pioglitazone Hydrochloride and Fluvastatin Sodium Drug–Drug Systems;Pharmaceuticals;2023-05-24

2. Ball-Milling Preparation of the Drug–Drug Solid Form of Pioglitazone-Rosuvastatin at Different Molar Ratios: Characterization and Intrinsic Dissolution Rates Evaluation;Pharmaceutics;2023-02-13

3. Importance of thorough tissue and cellular level characterization of targeted drugs in the evaluation of pharmacodynamic effects;PLOS ONE;2019-11-14

4. Maternal Metabolism and Vascular Adaptation in Pregnancy: The PPAR Link;Trends in Endocrinology & Metabolism;2017-01

5. Contemporary and Novel Therapeutic Options for Hypertriglyceridemia;Clinical Therapeutics;2015-12